ACRO Biomedical
Kaohsiung, Taiwan· Est.
Taiwanese collagen‑device maker leveraging scCO₂ decellularization for regenerative medicine and wound‑care solutions.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwanese collagen‑device maker leveraging scCO₂ decellularization for regenerative medicine and wound‑care solutions.
Regenerative MedicineWound CareDermatologyOphthalmologyOrthopedicsDentistry
Technology Platform
Proprietary supercritical CO₂ (scCO₂) decellularization of animal tissues to produce sterile, low‑immunogenic collagen scaffolds for medical device and regenerative applications.
Opportunities
Expansion into global regenerative‑medicine markets and diversification into bioelectronics applications leveraging scCO₂‑enhanced collagen.
Risk Factors
Regulatory approval timelines, supply‑chain reliance on animal tissues, and competition from larger medtech firms.
Competitive Landscape
Competes with established collagen‑matrix providers such as Integra and Medtronic; differentiation stems from its scCO₂ processing which offers superior sterility and reduced immunogenicity.